Sf-Stk kinase activity and the Grb2 binding site are required for Epo-independent growth of primary erythroblasts infected with Friend virus

被引:44
作者
Finkelstein, LD
Ney, PA
Liu, QP
Paulson, RF
Correll, PH
机构
[1] Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA
[2] St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA
关键词
erythroleukemia; receptor; tyrosine kinase; Stk; Fv2; signal transduction;
D O I
10.1038/sj.onc.1205442
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
During the initial stage of Friend virus-induced erythro-leukemia in mice, interaction of the viral protein gp55 with the erythropoietin receptor, and other host factors, drives the expansion of erythroid precursor cells. Recently, we demonstrated that the Friend virus susceptibility locus, Fv2, which is required for the expansion of infected cells, encodes a naturally occurring, N-terminally truncated form of the Stk receptor tyrosine kinase (Sf-Stk). Here we show that in vitro expression of Sf-Stk confers Friend virus sensitivity to erythroid progenitor cells from Fv2(rr) mice. Furthermore, our data reveal that Sf-Stk kinase activity and Y436, but not Y429, are required for Epo-independent colony formation following Friend virus infection. Introduction of a mutation that results in failure to bind Grb2 abrogates the ability of Sf-Stk to induce colonies in response to Friend virus, while the Grb2 binding site from EGFR restores this response. Consistent with the ability of Grb2 to recruit SOS and Gab1, the Ras/MAPK and PI3K pathways are activated by Sf-Stk, and both of these pathways are required for gp55-mediated erythroblast proliferation. These data clearly demonstrate a requirement for signaling through Sf-Stk in the Epo-independent expansion of Friend virus-infected cells, and suggest a pivotal role for Grb2 in this response.
引用
收藏
页码:3562 / 3570
页数:9
相关论文
共 38 条
[31]   Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1 [J].
Piao, XH ;
Paulson, R ;
vanderGeer, P ;
Pawson, T ;
Bernstein, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (25) :14665-14669
[32]   Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor [J].
Santoro, MM ;
Penengo, L ;
Minetto, M ;
Orecchia, S ;
Cilli, M ;
Gaudino, G .
ONCOGENE, 1998, 17 (06) :741-749
[33]   Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas [J].
Schmidt, L ;
Duh, FM ;
Chen, F ;
Kishida, T ;
Glenn, G ;
Choyke, P ;
Scherer, SW ;
Zhuang, ZP ;
Lubensky, I ;
Dean, M ;
Allikmets, R ;
Chidambaram, A ;
Bergerheim, UR ;
Feltis, JT ;
Casadevall, C ;
Zamarron, A ;
Bernues, M ;
Richard, S ;
Lips, CJM ;
Walther, MM ;
Tsui, LC ;
Geil, L ;
Orcutt, ML ;
Stackhouse, T ;
Lipan, J ;
Slife, L ;
Brauch, H ;
Decker, J ;
Niehans, G ;
Hughson, MD ;
Moch, H ;
Storkel, S ;
Lerman, MI ;
Linehan, WM ;
Zbar, B .
NATURE GENETICS, 1997, 16 (01) :68-73
[34]   THE V-SEA ONCOGENE OF AVIAN ERYTHROBLASTOSIS RETROVIRUS S13 - ANOTHER MEMBER OF THE PROTEIN-TYROSINE KINASE GENE FAMILY [J].
SMITH, DR ;
VOGT, PK ;
HAYMAN, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (14) :5291-5295
[35]   SPECIFIC MOTIFS RECOGNIZED BY THE SH2 DOMAINS OF CSK, 3BP2, FPS FES, GRB-2, HCP, SHC, SYK, AND VAV [J].
SONGYANG, Z ;
SHOELSON, SE ;
MCGLADE, J ;
OLIVIER, P ;
PAWSON, T ;
BUSTELO, XR ;
BARBACID, M ;
SABE, H ;
HANAFUSA, H ;
YI, T ;
REN, R ;
BALTIMORE, D ;
RATNOFSKY, S ;
FELDMAN, RA ;
CANTLEY, LC .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (04) :2777-2785
[36]   Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis [J].
Stefan, M ;
Koch, A ;
Mancini, A ;
Mohr, A ;
Weidner, KM ;
Niemann, H ;
Tamura, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (05) :3017-3023
[37]   Erythropoietin and friend virus gp55 activate different JAK/STAT pathways through the erythropoietin receptor in erythroid cells [J].
Yamamura, Y ;
Senda, H ;
Kageyama, Y ;
Matsuzaki, T ;
Noda, M ;
Ikawa, Y .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (03) :1172-1180
[38]  
ZHEN Z, 1994, ONCOGENE, V9, P1691